Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Participant has provided informed consent~* History of migraine (with or without aura) for ≥ 12 months before screening~* ≥ 4 migraine days per month on average across the 3 months prior to screening~* Treatment with 1 oral migraine preventive medication and/or concomitant use of OnabotulinumtoxinA injections for migraine prevention.~* Participant reports to their provider intolerance or insufficient response with their current preventative treatment~Exclusion Criteria:~* History of cluster headache or hemiplegic migraine headache~* Unable to differentiate migraine from other headaches~* Evidence of substance-related disorders~* Active chronic pain syndromes (eg, fibromyalgia and chronic pelvic pain)~* No therapeutic response with \> 3 migraine preventive medication categories~* Used a prohibited medication, device, or procedure~* Other clinically significant disorder, condition, or disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Erenumab (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).